Date:8/2/2011

Generic CNS-9,9909,990-8,5748,574-1717CNS 305,02527,225332,250320,63628,530349,166(5)(5)(5)PainProprietary PainFENTORA41,9109,51651,42638,8615,66144,52286816Other Proprietary Pain----4949-(100)(100)Generic PainACTIQ14,60715,38729,99414,47114,06728,538195Generic OTFC6,015-6,01511,535-11,535(48)-(48)AMRIX13,554-13,55428,548-28,548(53)-(53)Generic AMRIX11,420-11,420---100-100Other Generic Pain-28,22428,224-21,55621,556-3131Pain87,50653,127140,63393,41541,333134,748(6)294OncologyProprietary OncologyTREANDA125,847-125,84799,732-99,73226-26Other Proprietary Oncology5,01721,69926,7166,25318,76925,022(20)167Generic Oncology-6,1886,188-5,7045,704-88Oncology130,86427,887158,751105,98524,473130,458231422OtherOther Proprietary4,7261,8046,5302,8831,7544,63764341Other Generic4,53687,40091,9363,05890,36893,42648(3)(2)Other9,26289,20498,4665,94192,12298,06356(3)0$
532,657$ 197,443$
730,100$
525,977$ 186,458$
712,4351%6%2%Six Months Ended%June 30,Increase20112010(Decrease)United StatesEuropeTotalUnited StatesEuropeTotalUnited StatesEuropeTotalSales:CNSProprietary CNSPROVIGIL$
481,027$   28,515$
509,542$
513,151$   34,130$
547,281(6%)(16%)(7%)NUVIGIL110,608-110,60875,890-75,89046-46GABITRIL19,8032,25422,05719,4172,48621,9032(9)1Other Proprietary CNS-4,9614,961-5,6585,658-(12)(12)Generic CNS-19,76519,765-10,88510,885-8282CNS 611,43855,495666,933608,45853,159661,617041PainProprietary PainFENTORA80,95316,87497,82777,3419,39086,73158013Other Proprietary Pain-6161-108108-(44)(44)Generic PainACTIQ30,09328,05658,14929,41132,55861,9692(14)(6)Generic OTFC15,038-15,03824,314-24,314(38)-(38)AMRIX36,586-36,58653,683-53,683(32)-(32)Generic AMRIX11,420-11,420---100-100Other Generic Pain-52,09052,090-23,69823,698-120120Pain174,09097,081271,171184,74965,754250,503(6)488OncologyProprietary OncologyTREANDA243,572-243,572180,989-180,98935-35Other Proprietary Oncology10,52041,43351,95310,80838,96049,768(3)64Generic Oncology-12,36612,366-9,8589,858-2525Oncology254,09253,
'/>"/>

SOURCE Cephalon, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales